Article

Mitomycin C solution approved for glaucoma

Mobius Therapeutics has received final approval from the FDA for use of its mitomycin C ophthalmic solution (Mitosol) in glaucoma surgery. The company can begin marketing and producing the drug immediately.

St. Louis-Mobius Therapeutics has received final approval from the FDA for use of its mitomycin C ophthalmic solution (Mitosol) in glaucoma surgery. The company can begin marketing and producing the drug immediately.

“The approval of [the solution] for use in glaucoma surgery represents the culmination of more than 5 years of work,” said Ed Timm, president of Mobius Therapeutics. “It will provide surgeons, hospitals, and patients with enhanced convenience, safety, and consistency in the surgical treatment of glaucoma.”

The antifibrotic agent delivery system enables a precise dose of mitomycin C to be delivered to ophthalmic surgeons for use in procedures without any change to their current technique, according to the company, which is awaiting decisions from the FDA regarding refractive and corneal indications for the solution.

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.